DDInter512 DDInter1016
Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated. The presence of deuterium in deutetrabenazine increases the half-lives of the active metabolite and prolongs their pharmacological activity by attenuating CYP2D6 metabolism of the compound. This allows less frequent dosing and a lower daily dose with improvement in tolerability. Decreased plasma fluctuations of deutetrabenazine due to attenuated metabolism may explain a lower incidence of adverse reactions associated with deutetrabenazine. Deutetrabenazine is a racemic mixture containing RR-Deutetrabenazine and SS-Deutetrabenazine [FDA Label]. Huntington's disease (HD) is a hereditary, progressive neurodegenerative disorder characterized by motor dysfunction,
Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in patients with cirrhosis.[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.
Deutetrabenazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Deutetrabenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Deutetrabenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fedratinib
Deutetrabenazine {u} may lead to a major life threatening interaction when taken with {v} Dacomitinib
Deutetrabenazine {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Deutetrabenazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Deutetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin
Deutetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Deutetrabenazine may lead to a major life threatening interaction when taken with Dacomitinib
Deutetrabenazine may lead to a major life threatening interaction when taken with Macimorelin